Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 28HER2-positive Breast Cancer 4Neoplasms 3Multiple Myeloma 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Endometrial Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Salivary Gland Neoplasms 1Resectable HER2-positive Breast Cancer 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1

Interventions

pembrolizumab 4atezolizumab 3Cetuximab 3olaparib 2Trastuzumab 2Docetaxel 2zimberelimab 1tocilizumab 1spartalizumab 1ribociclib 1pralsetinib 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1ipatasertib 1inavolisib 1fludarabine phosphate 1fludarabine 1entrectinib 1encorafenib 1cemiplimab 1binimetinib 1anlotinib 1amivantamab 1alectinib 1adagrasib 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × pertuzumab × 90 days × Clear all
NCT02320435 2026-05-12

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Hoffmann-La Roche

Phase 3 Active not recruiting
154 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡